Incyte Corp (INCY)
51.74
+0.09
(+0.17%)
USD |
NASDAQ |
Apr 24, 16:00
52.00
+0.26
(+0.50%)
Pre-Market: 08:54
Incyte SG&A Expense (Quarterly): 293.90M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 293.90M |
September 30, 2023 | 267.90M |
June 30, 2023 | 283.90M |
March 31, 2023 | 315.60M |
December 31, 2022 | 272.80M |
September 30, 2022 | 266.50M |
June 30, 2022 | 253.30M |
March 31, 2022 | 209.60M |
December 31, 2021 | 226.16M |
September 30, 2021 | 190.70M |
June 30, 2021 | 168.90M |
March 31, 2021 | 153.80M |
December 31, 2020 | 167.00M |
September 30, 2020 | 120.80M |
June 30, 2020 | 118.00M |
March 31, 2020 | 111.10M |
December 31, 2019 | 136.21M |
September 30, 2019 | 102.60M |
June 30, 2019 | 105.90M |
March 31, 2019 | 123.98M |
December 31, 2018 | 108.36M |
September 30, 2018 | 96.52M |
June 30, 2018 | 108.03M |
March 31, 2018 | 121.50M |
December 31, 2017 | 97.73M |
Date | Value |
---|---|
September 30, 2017 | 91.26M |
June 30, 2017 | 90.07M |
March 31, 2017 | 87.23M |
December 31, 2016 | 96.08M |
September 30, 2016 | 75.78M |
June 30, 2016 | 66.79M |
March 31, 2016 | 64.60M |
December 31, 2015 | 52.47M |
September 30, 2015 | 47.60M |
June 30, 2015 | 51.68M |
March 31, 2015 | 44.87M |
December 31, 2014 | 48.45M |
September 30, 2014 | 39.45M |
June 30, 2014 | 40.90M |
March 31, 2014 | 36.97M |
December 31, 2013 | 38.03M |
September 30, 2013 | 26.45M |
June 30, 2013 | 23.25M |
March 31, 2013 | 22.26M |
December 31, 2012 | 23.73M |
September 30, 2012 | 20.52M |
June 30, 2012 | 19.72M |
March 31, 2012 | 21.40M |
December 31, 2011 | 21.15M |
September 30, 2011 | 14.28M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
102.60M
Minimum
Sep 2019
315.60M
Maximum
Mar 2023
198.14M
Average
190.70M
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
Novartis AG | 3.444B |
MorphoSys AG | -9.867M |
Illumina Inc | 485.00M |
Biogen Inc | 608.50M |
Pfizer Inc | 4.575B |